
Hepatitis C virus (HCV) has contributed to more US patient deaths than the next 60 reportable infectious diseases combined. The United States Preventive Services Task Force has issued updated guidelines on screening for HCV that account for the larger proportion of this patient group that now includes persons who inject drugs, as well as the shift from interferon-based therapy to regimens composed of direct-acting antiviral (DAA) medications.






























